Current Protocols in Laboratory Diagnosis, Genotyping, and Treatment of Burkholderia pseudomallei

Zueter, AbdelRahman; Sawan, Hana M.; Zaiter, Amani; Harun, Azian

doi:10.1016/j.clinmicnews.2022.01.003

Cited by 3 publications

(2 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of selected studies have been conducted in the last decade, mostly from 2011 to 2022 (97.5%). Regarding the study area, the primarily selected studies were retrieved in databases from 12 countries in the endemic area of Asia (28/40, 70.0%), in which 14 studies (35.0%) were found in Southeast Asia [8,12,[20][21][22][23][24][25][26][27][28][29][30][31], and seven studies (17.5%) were found in South Asia [19,[32][33][34][35][36][37] and East Asia [38][39][40][41][42][43][44]. Nine studies were conducted in Australia (22.5%) [45][46][47][48][49][50][51][52][53], and three studies were performed in North, South, and Central America (7.5%) [54][55][56] (Figure -2).…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

A systematic review and meta-analysis of the global prevalence and relationships among Burkholderia pseudomallei sequence types isolated from humans, animals, and the environment

Laklaeng,

Phu,

Songsri

et al. 2024

Vet World

View full text Add to dashboard Cite

Background and Aim: Burkholderia pseudomallei, a highly pathogenic bacterium responsible for melioidosis, exhibits ecological ubiquity and thrives within soil and water reservoirs, posing significant infection risks to humans and animals through direct contact. The aim of this study was to elucidate the genetic diversity and prevalence patterns of B. pseudomallei sequence types (STs) across a global spectrum and to understand the relationships between strains isolated from different sources. Materials and Methods: We performed a systematic review and meta-analysis in this study. Extensive research was carried out across three comprehensive databases, including PubMed, Scopus, and ScienceDirect with data collected from 1924 to 2023. Results: A total of 40 carefully selected articles contributed 2737 B. pseudomallei isolates attributed to 729 distinct STs and were incorporated into the systematic review. Among these, ST46 emerged as the most prominent, featuring in 35% of the articles and demonstrating a dominant prevalence, particularly within Southeast Asia. Moreover, ST51 consistently appeared across human, animal, and environmental studies. Subsequently, we performed a meta-analysis, focusing on nine specific STs: ST46, ST51, ST54, ST70, ST84, ST109, ST289, ST325, and ST376. Surprisingly, no statistically significant differences in their pooled prevalence proportions were observed across these compartments for ST46, ST70, ST289, ST325, and ST376 (all p > 0.69). Conversely, the remaining STs, including ST51, ST54, ST84, and ST109, displayed notable variations in their prevalence among the three domains (all p < 0.04). Notably, the pooled prevalence of ST51 in animals and environmental samples surpassed that found in human isolates (p < 0.01). Conclusion: To the best of our knowledge, this study is the first systematic review and meta-analysis to investigate the intricate relationships between STs and their sources and contributes significantly to our understanding of B. pseudomallei diversity within the One Health framework. Keywords: Burkholderia pseudomallei, melioidosis, meta-analysis, One Health, sequence type, systematic review.

show abstract

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

A systematic review and meta-analysis of the global prevalence and relationships among Burkholderia pseudomallei sequence types isolated from humans, animals, and the environment

Laklaeng,

Phu,

Songsri

et al. 2024

Vet World

View full text Add to dashboard Cite

show abstract

“…Presently the drug doxycycline is widely used as one of the most efficient therapeutic strategies for infection (Sridharan et al, 2021). However, studies reported that the B. pseudomallei bacteria also shows resistance to doxycycline while testing against the drug with different strains (Zueter et al, 2022). This bacterium is also naturally resistant to many antibiotics, including penicillin, cephalosporins, macrolides, rifamycins, polymyxins, and aminoglycosides (Di Fiore et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

In-silico Prediction of Drug Target, Molecular Modeling, and Docking Study of Potential Inhibitors against Burkholderia pseudomallei

Satpathy¹

2023

J Biochem Technol

View full text Add to dashboard Cite

The infection of the Burkholderia pseudomallei causes the disease melioidosis. for which the treatment method takes longer time, and sometimes it is difficult to completely eradicate the bacteria from the body. Moreover, its antibiotic resistance in nature created great concern in recent times. Hence, there is an urgent requirement to identify new drug molecules that can improve the current process of treatments and reduce the risk to people. This study analyzed the pyrimidine metabolic pathways of Burkholderia pseudomallei strain K96243, and UMP (Uridine monophosphate/Uridylate) kinase enzyme was selected as the drug target. After structure prediction by the AlphaFold server, the validation of the structure was performed by using Procheck, Verify3D, and Errat tool. Further, six probable inhibitor molecules were selected from the PubChem database, including the natural inhibitor of the enzyme, Uridine triphosphate (UTP). The molecular docking study predicted that the UTP (CID 6133) had the highest docking score, followed by another compound PubChem (Compound ID) CID 284262. Then, Toxicity and ADMET properties were computed and analyzed. Further, a 5 nanosecond molecular dynamics simulation of the complex of UMP-Kinase and CID 284262 was performed by using the Gromacs 5.1.1 software to analyze the stability of the best complex. It was predicted that the CID 284262 might be considered a suitable inhibitor of the enzyme.

show abstract

Comprehensive approaches for the detection of Burkholderia pseudomallei and diagnosis of melioidosis in human and environmental samples

Oslan

Yusoff

Mazlan

et al. 2022

Microbial Pathogenesis

View full text Add to dashboard Cite

Current Protocols in Laboratory Diagnosis, Genotyping, and Treatment of Burkholderia pseudomallei

Cited by 3 publications

References 75 publications

A systematic review and meta-analysis of the global prevalence and relationships among Burkholderia pseudomallei sequence types isolated from humans, animals, and the environment

A systematic review and meta-analysis of the global prevalence and relationships among Burkholderia pseudomallei sequence types isolated from humans, animals, and the environment

In-silico Prediction of Drug Target, Molecular Modeling, and Docking Study of Potential Inhibitors against Burkholderia pseudomallei

Comprehensive approaches for the detection of Burkholderia pseudomallei and diagnosis of melioidosis in human and environmental samples

Contact Info

Product

Resources

About